Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 10Active not recruiting 8Terminated 2Not yet recruiting 2Completed 2Suspended 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neoplasms 1Medulloblastoma 1Glioblastoma 1

Interventions

pembrolizumab 111Carboplatin 45Nivolumab 41Paclitaxel 34Cyclophosphamide 32Cisplatin 32Gemcitabine 30atezolizumab 27Specimen Handling 25venetoclax 24Magnetic Resonance Spectroscopy 24Pemetrexed 23fludarabine 22Biopsy 22Radiotherapy 21Ipilimumab 21Docetaxel 21Bevacizumab 21Azacitidine 21Radiosurgery 18durvalumab 17Fluorouracil 17Dexamethasone 17Cetuximab 16fludarabine phosphate 14Trastuzumab 14Leucovorin 13Cytarabine 13tislelizumab 12olaparib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Lomustine × 1 year × Clear all
NCT03382977 2026-05-08

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

VBI Vaccines Inc.

Phase 1/2 Terminated
70 enrolled
CNS

Glioblastoma, Neoplasms

NCT04402073 2025-10-23

PersoMed-I

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Terminated
20 enrolled
CNS

Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡